NovoCure Ltd — Director's Dealing 2021

Sep 7, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NovoCure Ltd (NVCR)
CIK: 0001645113
Period of Report: 2021-09-02

Reporting Person: Shah Pritesh (Chief Commercial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-09-02	Ordinary Shares	S	156	$138.232	Disposed	74013	Direct
2021-09-03	Ordinary Shares	S	321	$138.273	Disposed	73692	Direct
2021-09-03	Ordinary Shares	S	150	$139.238	Disposed	73542	Direct
2021-09-03	Ordinary Shares	S	30	$140.18	Disposed	73512	Direct

Footnotes

F1: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2: On September 3, 2021, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Shah, Mr. Shah sold 321 shares in multiple trades at prices ranging from $137.75 to $138.56. The price reported above reflects the weighted average sale price. Mr. Shah hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected.

F3: On September 3, 2021, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Shah, Mr. Shah sold 150 shares in multiple trades at prices ranging from $138.81 to $139.78. The price reported above reflects the weighted average sale price. Mr. Shah hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected.

F4: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Shah.